Adaptive Endpoints Selection with Application in Rare Disease

References

• Bauer, P. (1989), “Multistage Testing with Adaptive Designs,” Biometrie und Informatik in Medizin und Biologie, 20, 130–148.
   Google Scholar
• Bauer, P., and Koenig, F. (2006), “The Reassessment of Ttrial Perspectives from Interim Data–A Critical View,” Statistics in Medicine, 25, 23–36. DOI: 10.1002/sim.2180.
   PubMed Web of Science ®Google Scholar
• Bauer, P., and Kohne, K. (1994), “Evaluation of Experiments with Adaptive Interim Analyses,” Biometrics, 50, 1029–1041.
   PubMed Web of Science ®Google Scholar
• Beckman, R. A., and Chen, C. (2019), “Informational Designs and Potential Applications to Rare Disease,” in Handbook of Biomarkers and Precision Medicine, eds. C. Carini, M. Fidock, and A. van Gool, pp. 183–187, New York: Chapman and Hall/CRC.
   Google Scholar
• Brannath, W., Posch, M., and Bauer, P. (2002), “Recursive Combination tests’, Journal of the American Statistical Association, 97, 236–244. DOI: 10.1198/016214502753479374.
   Web of Science ®Google Scholar
• Bretz, F., Koenig, F., Brannath, W., Glimm, E., and Posch, M. (2009), “Adaptive Designs for Confirmatory Clinical Trials,” Statistics in Medicine, 28, 1181–1217. DOI: 10.1002/sim.3538.
   PubMed Web of Science ®Google Scholar
• Bretz, F., Schmidli, H., König, F., Racine, A., and Maurer, W. (2006), “Confirmatory Seamless Phase ii/iii Clinical Trials with Hypotheses Selection at Interim: General Concepts,” Biometrical Journal: Journal of Mathematical Methods in Biosciences, 48, 623–634. DOI: 10.1002/bimj.200510232.
   PubMed Web of Science ®Google Scholar
• Chen, C., Li, N., Shentu, Y., Pang, L., and Beckman, R. A. (2016), “Adaptive Informational Design of Confirmatory Phase iii Trials with an Uncertain Biomarker Effect to Improve the Probability of Success,” Statistics in Biopharmaceutical Research, 8, 237–247. DOI: 10.1080/19466315.2016.1173582.
   Web of Science ®Google Scholar
• Chen, L. M., Ibrahim, J. G., and Chu, H. (2014), “Flexible Stopping Boundaries When Changing Primary Endpoints After Unblinded Interim Analyses,” Journal of Biopharmaceutical Statistics, 24, 817–833. DOI: 10.1080/10543406.2014.901341.
   PubMed Web of Science ®Google Scholar
• Congress, U. (1983), “Orphan Drug Act: To Amend the Federal Food, Drug, and Cosmetic Act to Facilitate the Development of Drugs for Rare Diseases and Conditions, and for other Purposes,” Public Law, 97–414.
   Google Scholar
• FDA (2019a), “Adaptive Designs for Clinical Trials of Drugs and Biologics,” Center for Biologics Evaluation and Research (CBER).
   Google Scholar
• FDA (2019b), “Rare Diseases: Common Issues in Drug Development; Draft Guidance for Industry,” Pharmaceuticals Policy and Law, 11, 345–52.
   Google Scholar
• Finner, H., and Strassburger, K. (2002), “The Partitioning Principle: A Powerful Tool in Multiple Decision Theory,” Annals of Statistics, 30, 1194–1213.
   Web of Science ®Google Scholar
• Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., Merkel, P. A. et al. (2009), “Clinical Research for Rare Disease: Opportunities, Challenges, and Solutions,” Molecular Genetics and Metabolism, 96, 20–26. DOI: 10.1016/j.ymgme.2008.10.003.
   PubMed Web of Science ®Google Scholar
• Hellmich, M., and Hommel, G. (2004), “Multiple Testing in Adaptive Designs–A Review,” in Recent Developments in Multiple Comparison Procedures, eds. Y. Benjamini, F. Bretz, and S. Sarkar, pp. 33–47, Beachwood, OH: Institute of Mathematical Statistics.
   Google Scholar
• Hung, J. H., Wang, S.-J., and O’Neill, R. T. (2006), “Methodological Issues with Adaptation of Clinical Trial Design,” Pharmaceutical Statistics, 5, 99–107. DOI: 10.1002/pst.219.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., and Wittes, J. (1988), “The B-Value: A Tool for Monitoring Data,” Biometrics, 44, 579–585. DOI: 10.2307/2531870.
   PubMed Web of Science ®Google Scholar
• Lehmacher, W., and Wassmer, G. (1999), “Adaptive Sample Size Calculations in Group Sequential Trials,” Biometrics, 55, 1286–1290. DOI: 10.1111/j.0006-341x.1999.01286.x.
   PubMed Web of Science ®Google Scholar
• Liu, Y., and Xu, H. (2021), “Sample Size Re-estimation for Pivotal Clinical Trials,” Contemporary Clinical Trials, 102, 106215. DOI: 10.1016/j.cct.2020.106215.
   PubMed Web of Science ®Google Scholar
• Mehta, C., Schäfer, H., Daniel, H., and Irle, S. (2014), “Biomarker Driven Population Enrichment for Adaptive Oncology Trials with Time to Event Endpoints,” Statistics in Medicine, 33, 4515–4531. DOI: 10.1002/sim.6272.
   PubMed Web of Science ®Google Scholar
• Müller, H.-H., and Schäfer, H. (2004), “A General Statistical Principle for Changing a Design Any Time during the Course of a Trial,” Statistics in Medicine, 23, 2497–2508. DOI: 10.1002/sim.1852.
   PubMed Web of Science ®Google Scholar
• Sarkar, S. K. (1998), “Some Probability Inequalities for Ordered mtp2 Random Variables: A Proof of the Simes Conjecture,” Annals of Statistics, 26, 494–504.
   Web of Science ®Google Scholar
• Stallard, N., and Todd, S. (2011), “Seamless Phase ii/iii Designs,” Statistical Methods in Medical Research, 20, 623–634. DOI: 10.1177/0962280210379035.
   PubMed Web of Science ®Google Scholar
• Stefansson, G., Kim, W., and Hsu, J. (1988), “On Confidence Sets in Multiple Comparisons,” Statistical Decision Theory and Related Topics IV, 2, 89–104.
   Google Scholar
• Van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010), “A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe’s Disease,” New England Journal of Medicine, 362, 1396–1406. DOI: 10.1056/NEJMoa0909859.
   PubMed Web of Science ®Google Scholar